Casa G / Delfino Lozano

first_imgCasa G / Delfino LozanoSave this projectSaveCasa G / Delfino Lozano Manufacturers: Aceros Ocotlan, MOOMA Mosaicos, TEJAVAL, URREACollaborators:Bernardo Sánchez, Andrés CovarrubiasStructural Engineer:Ing. Delfino Lozano ArmentaCarpentry:Mauricio VillalbazoWindows:Alberto Flores, Vidrios y Aluminios REYLOElectrical/Plumbing:Eugenio MartinezCity:ZapopanCountry:MexicoMore SpecsLess SpecsSave this picture!© César BéjarRecommended ProductsWindowsStudcoSteel Window Reveal – EzyRevealEnclosures / Double Skin FacadesFranken-SchotterFacade System –  LINEAWindowsJansenWindows – Janisol PrimoEnclosures / Double Skin FacadesRodecaRound Facade at Omnisport Arena ApeldoornText description provided by the architects. Casa G is a family rest house, with a game room and a terrace to host the owner’s social activities, located in the northwest area of Zapopan, on a 1000m2 land oriented north-south. The land presented an ascending topography and existing adjoining walls.Save this picture!© César BéjarSave this picture!Lower Floor PlanSave this picture!© César BéjarThe length of the land allowed to trace a central axis that connected the main spaces of the house and its unevenness originated a perpendicular axis where a retaining wall was raised, generating two clearly defined areas: social on the lower part, and private on the highest part of the land.Save this picture!© César BéjarThe social area is accessed through a hall with a curved vault that registers the transition between the exterior and interior, where the image of the stonewall contrasts the modulation logic of the vaults that cover the terrace. Alongside, there is an esplanade that is visually connected by the same wall that extends to a staircase. This space is complemented by a visual focus point generated by a stone fountain with a tree, and the strategic presence of a mast, designed to eventually hold a piñata.Save this picture!© César BéjarSave this picture!© César BéjarThe interaction between the social and the private develops from the staircase that obliterates the natural unevenness of the land; the stonewall now merges with a bench where the garden and a weeping willow tree frame the facade of the house. On the west side, there is a brick-wall volume destined to be a game room, absorbing the space generated by the rooftop of the terrace as it is suspended above the garage. The structural solution based on IPR beams liberated both the terrace and the garage from columns, as well as it physically linked the social and private areas.Save this picture!© César BéjarSave this picture!Upper Floor PlanSave this picture!© César BéjarThe private area was resolved with a side entry that goes along the unevenness of the land, culminating with brick latticework and mirror-still water, emphasizing the main entrance of the house. In the interior, a distributor conducts to three clearly defined spaces: on one side, the kitchen with a garden view and ventilation to the entrance hall; on the opposite side, a guest area formed by a toilet and a TV room, which can also be used as a guest room; on the front, through a wooden frame, a set of spaces aligned to an imaginary symmetry axis, comprising a small garden with a tree, the dining room, the living room, and a small open terrace with a hanging hammock. The chimney located in the center of the house represents the medullary core of family life. Save this picture!© César BéjarTwo things were achieved from the effective use of natural light and the generation of crossing ventilation: provide the common spaces of the house with better views of the ensemble and bring privacy and comfort to each room, where the main room keeps the visual domain of the garden and the game room, while the second room keeps certain independence behind a distributor that holds a linen closet and the bathrooms of both rooms. There is a housing serving module and a maintenance cellar located on the back of the house. The rooftop of the house was used as a viewpoint to the landscape that can be appreciated from the highest point of the ensemble. For this, the installations were hidden and the coating used on the floor is the same as in the game room terrace.Save this picture!© César BéjarProject gallerySee allShow lessStanton Williams and Asif Khan Selected to Design Future Home for the Museum of LondonArchitecture NewsHou de Sousa Completes Construction on Raise/Raze and SticksArchitecture News Share Houses ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/792180/casa-g-delfino-lozano Clipboard Photographs:  César Béjar Manufacturers Brands with products used in this architecture project Area:  430 m² Year Completion year of this architecture project Mexico Projects Save this picture!© César Béjar+ 39 Share 2016 Architects: Delfino Lozano Area Area of this architecture projectcenter_img “COPY” ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/792180/casa-g-delfino-lozano Clipboard Year:  Photographs ArchDaily Casa G / Delfino Lozano CopyHouses•Zapopan, Mexico “COPY” CopyAbout this officeDelfino LozanoOfficeFollowProductsWoodSteelBrick#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesZapopanOn InstagramMexicoPublished on July 28, 2016Cite: “Casa G / Delfino Lozano” [Casa G / Delfino Lozano] 28 Jul 2016. ArchDaily. Accessed 11 Jun 2021. ISSN 0719-8884Read commentsBrowse the CatalogPanels / Prefabricated AssembliesTechnowoodPanel Façade SystemRailing / BalustradesMitrexIntegrated Photovoltaic Railing – BIPV RailingMetal PanelsAurubisPatinated Copper: Nordic Green/Blue/Turquoise/SpecialPlastics / FibersRodecaTranslucent Building Elements in Downton Primary SchoolSkylightsVELUX CommercialModular Skylights – LonglightBathroom FurnitureBradley Corporation USAToilet Partition CubiclesSignage / Display SystemsGoppionDisplay Case – One-offAcousticFabriTRAK®FabriFELT™ for Walls and CeilingsBoardsStructureCraftStructural Panel – Dowel Laminated TimberThermalSchöckInsulation – Isokorb® Concrete to SteelDoorsJansenSmoke Control Door – Economy 60Louvers / ShuttersShade FactorExternal Venetian BlindsMore products »Read commentsSave世界上最受欢迎的建筑网站现已推出你的母语版本!想浏览ArchDaily中国吗?是否翻译成中文现有为你所在地区特制的网站?想浏览ArchDaily中国吗?Take me there »✖You’ve started following your first account!Did you know?You’ll now receive updates based on what you follow! Personalize your stream and start following your favorite authors, offices and users.Go to my streamlast_img read more

Salesforce opens London Ohana Floor with free weekend & weeknight use for non-profits

first_imgMain image: Sadiq Khan and Dame Jayne-Anne Gadhia, UKI CEO, at the opening of Ohana Floor at Salesforce Tower, London Melanie May | 6 December 2019 | News AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis3 About Melanie May Melanie May is a journalist and copywriter specialising in writing both for and about the charity and marketing services sectors since 2001. She can be reached via www.thepurplepim.com. Salesforce opens London Ohana Floor with free weekend & weeknight use for non-profits “Today is a landmark moment for Salesforce in the UK, as we make significant investments to skill and train the workforce for the future, while also opening our first international Ohana Floor – an inspiring space for the whole community. We believe businesses have a responsibility to benefit everyone in society, so we must step up to meet that challenge. Today’s announcements underline our commitment to making sure the digital age works for everyone and helps generate equality for all.” Salesforce has opened a new hospitality space in Salesforce Tower London, which it is offering free to non-profits and community organisations at weekends and on weeknights.Salesforce’s Ohana Floor is a flexible space available for Salesforce employees, customers and partners, which will also be available for non-profits and local education groups on weeknights and weekends at no cost. Organisations can request to use the Ohana Floor now.Salesforce also has Ohana Floors in San Francisco, Indianapolis, and New York. This is its first international Ohana Floor. Each one is offered free of charge for events by organisations focusing on humanitarian or social causes, education or workforce development, or the environment. To date, events across Salesforce’s Ohana Floors have raised over $9.4 million for charity.At the opening of the Ohana Floor, Salesforce also announced grants totalling $1.25m to two charities as its latest commitment to supporting education and workforce development. It is giving a $750,000 grant to education charity Ark and a $500,000 grant to Ada, the National College for Digital Skills.The grants will support Ark in advancing mathematics education through its Mathematics Mastery programme, and Ada in scaling diversity in its digital apprenticeship programme.Salesforce also shared plans to expand its Pathfinder Training Program into the UK. One of the company’s workforce development initiatives, it is designed to address the skills gap by providing participants from diverse backgrounds the technical and business training they need to obtain jobs in the Salesforce ecosystem. This is the first time the programme has expanded outside of the US.At the event, Mayor of London Sadiq Khan recognised Salesforce as a member of the Good Work Standard, and said:“I’m delighted to help Salesforce open their new Ohana Floor and to accredit them to the Mayor’s Good Work Standard. Not only is Salesforce setting an example of how businesses can give back to the community, they are also joining a list of London employers committed to the very highest standards in employment practice.”Also speaking at the launch, Salesforce CEO, UKI, Dame Jayne-Anne Gadhia commented: Advertisement Tagged with: FREE Salesforce  245 total views,  2 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis3last_img read more

On the picket line

first_imgBosses retaliate against Hunts Point workersBusiness retaliation against union organizing is nothing new. Weak laws and minimal fines embolden corporations like Amazon to hire strikebreaking law firms to intimidate workers into voting down attempts to unionize their workplace. Workers who strike or successfully organize face the threat of losing their jobs.Teamsters Local 202 reports that at least 26 union members from Hunts Point Produce Market in New York City have been laid off since work resumed following the strike for a $1 an hour pay increase. These essential workers continued to work 12-hour shifts throughout the pandemic. Hunts Point Market is a vital link in the food distribution system for this country.Proving that the layoffs are retaliatory is difficult and labor laws don’t go far enough to protect workers’ organizing efforts. (tinyurl.com/87776sh8)Disabled workers fight in CincinnatiVisually impaired and blind workers, who are two-thirds of the workforce at a factory run by the Cincinnati Association of the Blind and Visually Impaired, have petitioned management to address unfair labor and safety concerns. After the factory reopened following a pandemic-related shutdown, management failed to follow seniority rehiring rules. The complaint states several blind workers have been unfairly targeted and not reinstated.Other workers were brought back and forced to work in different jobs for less pay. The company also removed safety barriers that had protected disabled workers from areas where heavy machinery is used. Dave Perry, a visually impaired member of Teamster Local 100 and factory worker, referenced Teamster organizers of the 1930s who preferred a short, page-long union contract. He said, “the bosses clearly seem to have more difficulty sticking to even that length of a contract without us making them do it.” (the Militant, March 8)Teachers union ties to Women’s HistoryPrior to the industrial revolution, teaching was a job for men. There was no public education system, and teaching was nothing like the profession it is today. Industrialization provided more work opportunities, and men moved on to better and higher paying jobs and away from teaching. Young women were tapped to become teachers to fill the gap, because of the expanding population in the late 19th century and the development of the public school system.Patriarchy still defined the field. Women were paid less than their male counterparts and were forced to leave their positions when they married. Men were the administrators of the public school system. Women responded to this exploitation by demanding better conditions and equal pay. The Chicago Teachers Federation was formed in 1897 by teachers Catherine Coggin and Margaret Haley. It grew into what is today the American Federation of Teachers, one of the most powerful unions in the country. By the 1940s, the AFT was collectively bargaining with school boards.Today, AFT and other teacher union locals in major cities across the country are fighting for the safety of their members. They are defying mayors and board of education officials by refusing to return to in-person classrooms until it is safe for both teachers and their students. They continue the legacy of the women who defied the patriarchal norms of the 19th and 20th centuries. (tinyurl.com/rnh957nw)FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare thislast_img read more

Glyphosate-resistant Weeds Found in Multiple Indiana Counties

first_img Facebook Twitter Glyphosate-resistant Weeds Found in Multiple Indiana Counties SHARE By Andy Eubank – Jul 8, 2012 Facebook Twitter As the summer drought continues, farmers across Indiana are struggling to control glyphosate-resistant weeds, says a Purdue Extension specialist.Farmers are seeing marestail, giant ragweed and common waterhemp throughout their fields this year, and the hot, dry weather is making it more difficult to get a firm grip on controlling them.According to Bill Johnson, marestail and giant ragweed are spread widely around the state. Waterhemp is mainly seen in southwest, northwest and east-central Indiana and glyphosate-resistant populations have now been confirmed in nine counties. Glyphosate-resistant Palmer amaranth has been confirmed in one county. Although glyphosate-resistant marestail is the primary concern in 2012 and can be found in most counties where soybeans are grown, waterhemp and giant ragweed are of growing importance.Johnson said marestail is extra problematic this summer because of the mild winter.“We didn’t get winterkill for the populations that emerged in the fall,” he said. “The ones that emerged this spring emerged very early and, because of the warm weather conditions, were able to grow unabated, and quickly became too large to control with labeled herbicide rates.”Glyphosate-resistant broadleaf weeds are a greater problem in soybean fields than in cornfields because there are fewer herbicides to control broadleaf weeds in a broadleaf crop such as soybean. In addition, the drought is causing the weeds to dry out and curl up, making it less sensitive to herbicides.Johnson said that as weeds show glyphosate resistance, farmers are turning to older herbicides – something he said is feasible but requires a lot of work and fine-tuning.Although crops that have a resistance to older broadleaf herbicides such as 2,4-D and dicamba are being developed, Johnson said it will be a few years before we are able to use them.Farmers in the southeast portion of Indiana saw a severe case of glyphosate-resistant weeds 10 years ago. The problem gradually spread.  Five years ago, glyphosate-resistant weeds became a statewide problem.Johnson said farmers should scout fields to determine where glyphosate-resistant weeds are worst, and know if the current treatment plan is effective.More information about glyphosate-resistant weeds is available in a series of publications from Purdue Extension – The Education Store at https://mdc.itap.purdue.edu/. Search glyphosate.Source: Purdue Ag Communications Home Indiana Agriculture News Glyphosate-resistant Weeds Found in Multiple Indiana Counties SHARE Previous articleTransferring Family AssetsNext articleGovernors Calling for State Action on E15 Commended Andy Eubanklast_img read more

Men’s Basketball cruise past Eastern Michigan, 87-69

first_imgKouat Noi had a career-high 27 points to lift the Horned Frogs to a dominant win. Photo by Cristian ArguetaSoto printKouat Noi had a career-high 27 points to lift the Horned Frogs to a dominant win. Photo by Cristian ArguetaSotoTCU men’s basketball rebounded from their first loss of the season as they cruised to an 87-69 victory over Eastern Michigan Monday night behind a career-high 27 points from forward Kouat Noi.“It sucks to lose,” Noi said. “This past week, we’ve been going hard every day and pushing each other, and it showed tonight.”In just his second game back from injury, the sophomore from Newcastle, Australia shot 11-15 from the field and 5-8 from three to go with four assists and two rebounds.“I’m always comfortable shooting the ball,” Noi said. “It was a good game today, and I give all the credit to my teammates for finding me when I was open.”Noi’s performance played a big part in TCU’s season-high 60.7 shooting percentage.The Horned Frogs stuttered out of the gates, as they missed nine of their first 11 shots and found themselves down 11-2 with 13:02 left in the first half.“This was going against zone for the first time, so you saw the struggles early,” said head coach Jamie Dixon.The Horned Frogs adjusted, and from there, it was all TCU.The long-awaited return of guard Jaylen Fisher finally paid off. While he officially returned in TCU’s previous game against Lipscomb, the junior only played seven minutes and did not score.In a span of 2:28, Fisher announced his return by hitting on three-straight three-point attempts. His electric shooting was part of a 20-6 run by the Horned Frogs, propelling them to a 35-24 halftime lead.Jaylen Fisher had 12 points in his first full game back from injury. Photo by Cristian ArguetaSoto“I just felt like that’s what the team needed then, you know what I mean, just a spark of the bench,” Fisher said.  “It was just a blessing for me to come in and do that.”Fisher finished the game with 12 points and five assists in 31 minutes played. He said after the game that his knee felt “not one hundred percent, but it will get there.”TCU thrived defensively, scoring 21 points off of 16 forced turnovers.“It kept us going in the first half and eventually got us going in some offense,” Dixon said. “We want our defense to lead to more offense. That’s something we need to do.”Kevin Samuel played a huge role in the efficiency that lifted the Horned Frogs to victory. Photo by Cristian ArguetaSotoLed by Noi and center Kevin Samuel in the second half, the Horned Frogs attacked from both outside the three-point line and inside the paint.Samuel finished the game with 15 points on 7-9 shooting to go with seven rebounds and two blocks.“You have Kouat and Jaylen, you know, they open up the floor with their shooting ability,” Samuel said. “It opens up the floor, so you can get me inside.”TCU shot 67 percent on 19 assists in the second half, including six three-pointers and five dunks.The victory pushes TCU’s record to 4-1 on the season, no longer in the top 25 after falling to Lipscomb.The Horned Frogs will return to the court at 6:30 p.m. on Friday to face Central Michigan at Schollmaier Arena.<span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span> First TCU spring game since 2018 gets fans primed for a highly-anticipated fall Another series win lands TCU Baseball in the top 5, earns Sikes conference award Facebook Linkedin Linkedin + posts TCU rowing program strengthens after facing COVID-19 setbacks Colin Post is a Sports Broadcasting and Journalism double-major from Houston, Texas. Along with sports writing, Colin hopes to work in sports announcing after he graduates. Twitter Colin Posthttps://www.tcu360.com/author/colin-post/ Colin Post Twitter Colin Posthttps://www.tcu360.com/author/colin-post/ Colin Posthttps://www.tcu360.com/author/colin-post/ Despite series loss, TCU proved they belong against No. 8 Texas Tech Previous articleWomen’s Basketball split games at SDSU Thanksgiving ClassicNext articleRevitalized organization to push for campus-wide sustainability Colin Post RELATED ARTICLESMORE FROM AUTHOR Facebook Colin Posthttps://www.tcu360.com/author/colin-post/ ReddIt Another series win lands TCU Baseball in the top 5, earns Sikes conference award ReddIt Taylor’s monster slam highlights big weekend for TCU Athletics TCU baseball finds their biggest fan just by saying hellolast_img read more

Home Office breaching Cabinet Office guidelines over surveillance consultation argue campaigners

first_img RSF condemns BBC broadcast ban as example of Chinese government reprisal News United KingdomEurope – Central Asia Protecting journalists Freedom of expression Safety of journalists remains active concern in Northern Ireland as BBC Panorama team is threatened Organisation A group of lawyers, civil liberty groups and trade unions have written to the Home Secretary Amber Rudd to ask her to re-run her consultation into new Codes of Practice required under the Investigatory Powers Act.The codes include over 400 pages of legal text, outlining how the powers in the IPA will be put into practice. However, the Home Office has allowed respondents just six weeks to give feedback.The Cabinet Office’s guidelines say that consultations should “Give enough information to ensure that those consulted understand the issues and can give informed responses.” However, the consultation includes just fifteen paragraphs to explain the content of the five documents.The letter’s signatories are calling for the Cabinet Office to publish more detailed information about the codes, including the changes made since Parliament saw them, followed by a full three months for consultation and to arrange briefings with lawyers, civil society and other interested groups.The Home Office has been compelled to publish the Codes of Practices after the Investigatory Powers Tribunal ruled that documents about the use of surveillance must be made public.Jim Killock, Executive Director of Open Rights Group said:“Amber Rudd wants to be trusted with even more powers to remove security at WhatsApp, yet she is running the flimsiest possible consultation process for her existing powers, designed to stop people from understanding whatever she is proposing.“She has also failed to explain to Parliament in what way she has changed the Codes from the drafts she showed Parliament. The changes we have detected include watering down strict obligations given to the agencies to more general guidance, by changing words like ‘must’ to ‘may’.”Thomas Hughes, Executive Director, ARTICLE 19 said:”The so-called consultation process on these Codes of Practice raises damning questions about the government’s approach to democratic participation and open and transparent processes. The Home Office has made it near impossible for any meaningful scrutiny, despite their complexity. A rushed-through consultation is no consultation at all. The Home Office must take immediate steps to ensure a consultation process that lives up to its name and supports the meaningful participation of civil society.”Rebecca Vincent, UK Bureau Director of Reporters Without Borders said:”We remain extremely worried by the implications of the Investigatory Powers Act for investigative journalism in the UK. The Home Office’s approach to the consultation on the proposed codes of practice presents further cause for concern. Civil society must be given the chance to meaningfully engage on these proposals, in the interest of transparency and accountability.” Solidarity with Swedish media outlet Realtid ahead of UK defamation case hearing Help by sharing this information News RSF_en to go furthercenter_img News March 23, 2021 Find out more News Follow the news on United Kingdom March 28, 2017 Home Office breaching Cabinet Office guidelines over surveillance consultation argue campaigners February 11, 2021 Find out more February 12, 2021 Find out more United KingdomEurope – Central Asia Protecting journalists Freedom of expression Receive email alertslast_img read more

Leadership Change at Cancer Support Community Pasadena

first_img Top of the News Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Business News EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS HerbeautyWant To Seriously Cut On Sugar? You Need To Know A Few TricksHerbeautyHerbeautyHerbeauty8 Easy Exotic Meals Anyone Can MakeHerbeautyHerbeautyHerbeauty9 Hollywood Divas Who Fell In Love With WomenHerbeautyHerbeautyHerbeauty8 Celebrities People Don’t Love AnymoreHerbeautyHerbeautyHerbeauty10 Questions To Start Conversation Way Better Than ‘How U Doing?’HerbeautyHerbeautyHerbeautyBaby Boom: The Stars Are Getting Busy In QuarantineHerbeautyHerbeauty Community News Name (required)  Mail (required) (not be published)  Website  Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. L-R: Clay Marquardt, President of the Board of Directors; Beverly Rouse, retiring Executive Director; Mario Haug, incoming Executive Director. Photo courtesy Cancer Support Community PasadenaBeverly Rouse will retire as Executive Director at Cancer Support Community Pasadena (CSCP) on June 30, 2014 after more than eight years of service. Originally known as The Wellness Community Foothills, Rouse led the name change to Cancer Support Community Pasadena in 2010 following the merger between The Wellness Community National and Gilda’s Clubs Worldwide. Since Rouse joined the CSCP team, programs have grown at the Pasadena facility to serve more than 1,000 people each year and another 1,000 people are reached through community outreach programs. Clay Marquardt, President of the CSCP Board of Directors, noted ”Beverly has provided strong and passionate leadership for Cancer Support Community. She has many friends and colleagues at CSCP and in the Pasadena area who have great admiration and respect for her.”Mario Haug will assume the Executive Director position on July 1, 2014. With extensive management and development experience from leadership posts at Goodwill Industries of Southern California, The Salvation Army, Southern California Division, USC, and Junior Achievement of Southern California, Haug is enthusiastic about leading the effort to extend CSCP services to more people facing cancer in the San Gabriel and San Fernando Valleys. Haug and his family reside in Sierra Madre. “We are delighted to welcome Mario Haug as CSCP’s new Executive Director and look forward to his leadership of the organization into the future,” noted Marquardt.Cancer Support Community Pasadena provides professionally led cancer support services at no charge to participants including weekly support groups, a robust education program, and weekly mind-body classes for people facing cancer.For further information: Contact Amy Bauer at (626) 796-1083 or online at www.cscpasadena.org. Community News Make a commentcenter_img People Leadership Change at Cancer Support Community Pasadena From STAFF REPORTS Published on Wednesday, June 11, 2014 | 11:35 am 3 recommended0 commentsShareShareTweetSharePin it Your email address will not be published. Required fields are marked * Subscribe First Heatwave Expected Next Week Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Virtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyCitizen Service CenterPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes More Cool Stuff Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadenalast_img read more

Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU…

first_imgConcomitant Use With Chemotherapy: Safety and efficacy of concomitant chemotherapy with Xofigo have not been established. Outside of a clinical trial, concomitant use of Xofigo in patients on chemotherapy is not recommended due to the potential for additive myelosuppression. If chemotherapy, other systemic radioisotopes, or hemibody external radiotherapy are administered during the treatment period, Xofigo should be discontinued Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU Cancers Symposium By Digital AIM Web Support – February 8, 2021 About NUBEQA ® (darolutamide) 2 NUBEQA is an androgen receptor inhibitor (ARi) with a distinct chemical structure that competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. 2 A Phase III study in metastatic hormone-sensitive prostate cancer (ARASENS) is ongoing. Information about this trial can be found at www.clinicaltrials.gov. On July 30th, 2019, the FDA approved NUBEQA ® (darolutamide) based on the ARAMIS trial, a randomized, double-blind, placebo-controlled, multi-center Phase III study, which evaluated the safety and efficacy of oral NUBEQA in patients with nmCRPC who were receiving a concomitant gonadotropin-releasing hormone (GnRH) analog or had a bilateral orchiectomy. In the clinical study, 1,509 patients were randomized in a 2:1 ratio to receive 600 mg of NUBEQA orally twice daily or androgen deprivation therapy (ADT) alone. The primary efficacy endpoint was metastasis-free survival (MFS) and secondary endpoints include overall survival (OS), time to pain progression and time to initiation of cytotoxic chemotherapy. Developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company, NUBEQA is indicated for the treatment of men with nmCRPC. 2 The approvals of NUBEQA in the U.S., European Union (EU), and other global markets have been based on the pivotal Phase III ARAMIS trial data evaluating the efficacy and safety of NUBEQA plus ADT compared to ADT alone. 2 Filings in other regions are underway or planned. INDICATION FOR NUBEQA (darolutamide) NUBEQA ® (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer. IMPORTANT SAFETY INFORMATION FOR NUBEQA (darolutamide) Embryo-Fetal Toxicity: Safety and efficacy of NUBEQA have not been established in females. NUBEQA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment with NUBEQA and for 1 week after the last dose. Adverse Reactions Serious adverse reactions occurred in 25% of patients receiving NUBEQA and in 20% of patients receiving placebo. Serious adverse reactions in ≥1 % of patients who received NUBEQA were urinary retention, pneumonia, and hematuria. Overall, 3.9% of patients receiving NUBEQA and 3.2% of patients receiving placebo died from adverse reactions, which included death (0.4%), cardiac failure (0.3%), cardiac arrest (0.2%), general physical health deterioration (0.2%), and pulmonary embolism (0.2%) for NUBEQA. Adverse reactions occurring more frequently in the NUBEQA arm (≥2% over placebo) were fatigue (16% vs 11%), pain in extremity (6% vs 3%) and rash (3% vs 1%). Clinically significant adverse reactions occurring in ≥2% of patients treated with NUBEQA included ischemic heart disease (4.0% vs 3.4% on placebo) and heart failure (2.1% vs 0.9% on placebo). Drug Interactions Effect of Other Drugs on NUBEQA– Combined P-gp and strong or moderate CYP3A4 inducers decrease NUBEQA exposure, which may decrease NUBEQA activity. Avoid concomitant use. Combined P-gp and strong CYP3A4 inhibitors increase NUBEQA exposure, which may increase the risk of NUBEQA adverse reactions. Monitor more frequently and modify NUBEQA dose as needed. Effects of NUBEQA on Other Drugs– NUBEQA inhibits breast cancer resistance protein (BCRP) transporter. Concomitant use increases exposure (AUC) and maximal concentration of BCRP substrates, which may increase the risk of BCRP substrate-related toxicities. Avoid concomitant use where possible. If used together, monitor more frequently for adverse reactions, and consider dose reduction of the BCRP substrate. NUBEQA inhibits OATP1B1 and OATP1B3 transporters. Concomitant use may increase plasma concentrations of OATP1B1 or OATP1B3 substrates. Monitor more frequently for adverse reactions and consider dose reduction of these substrates. Review the prescribing information of drugs that are BCRP, OATP1B1, and OATP1B3 substrates when used concomitantly with NUBEQA. For important risk and use information about NUBEQA, please see the accompanying full Prescribing Information. About Xofigo ® (radium Ra 223 dichloride) Injection 3 Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Important Safety Information for Xofigo ® (radium Ra 223 dichloride) Injection Warnings and Precautions: Bone Marrow Suppression: In the phase 3 ALSYMPCA trial, 2% of patients in the Xofigo arm experienced bone marrow failure or ongoing pancytopenia, compared to no patients treated with placebo. There were two deaths due to bone marrow failure. For 7 of 13 patients treated with Xofigo bone marrow failure was ongoing at the time of death. Among the 13 patients who experienced bone marrow failure, 54% required blood transfusions. Four percent (4%) of patients in the Xofigo arm and 2% in the placebo arm permanently discontinued therapy due to bone marrow suppression. In the randomized trial, deaths related to vascular hemorrhage in association with myelosuppression were observed in 1% of Xofigo-treated patients compared to 0.3% of patients treated with placebo. The incidence of infection-related deaths (2%), serious infections (10%), and febrile neutropenia (<1%) was similar for patients treated with Xofigo and placebo. Myelosuppression–notably thrombocytopenia, neutropenia, pancytopenia, and leukopenia–has been reported in patients treated with Xofigo.Monitor patients with evidence of compromised bone marrow reserve closely and provide supportive care measures when clinically indicated. Discontinue Xofigo in patients who experience life-threatening complications despite supportive care for bone marrow failure WhatsApp Twitter Pinterest Pinterest Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trialAbstract 239; February 11, 8:00am EST Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world studyAbstract 217; February 11, 8:00am EST Increased Fractures and Mortality in Combination With Abiraterone PlusPrednisone/Prednisolone: Xofigo is not recommended for use in combination with abiraterone acetate plus prednisone/prednisolone outside of clinical trials. At the primary analysis of the Phase 3 ERA-223 study that evaluated concurrent initiation of Xofigo in combination with abiraterone acetate plus prednisone/prednisolone in 806 asymptomatic or mildly symptomatic mCRPC patients, an increased incidence of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received Xofigo in combination with abiraterone acetate plus prednisone/prednisolone compared to patients who received placebo in combination with abiraterone acetate plus prednisone/prednisolone. Safety and efficacy with the combination of Xofigo and agents other than gonadotropin-releasing hormone analogues have not been established DASL-HiCaP: Darolutamide and standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation– Investigator-Initiated Research (IIR)Abstract TPS266; February 11, 8:00am EST Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial– Investigator-Initiated Research (IIR)Abstract TPS175; February 11, 8:00am EST Facebook Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAHAbstract 48; February 11, 8:00am EST Embryo-Fetal Toxicity: The safety and efficacy of Xofigo have not been established in females. Xofigo can cause fetal harm when administered to a pregnant female. Advise pregnant females and females of reproductive potential of the potential risk to a fetus. Advise male patients to use condoms and their female partners of reproductive potential to use effective contraception during and for 6 months after completing treatment with Xofigo Administration and Radiation Protection: Xofigo should be received, used, and administered only by authorized persons in designated clinical settings. The administration of Xofigo is associated with potential risks to other persons from radiation or contamination from spills of bodily fluids such as urine, feces, or vomit. Therefore, radiation protection precautions must be taken in accordance with national and local regulations Fluid Status: Dehydration occurred in 3% of patients on Xofigo and 1% of patients on placebo. Xofigo increases adverse reactions such as diarrhea, nausea, and vomiting, which may result in dehydration. Monitor patients’ oral intake and fluid status carefully and promptly treat patients who display signs or symptoms of dehydration or hypovolemia Injection Site Reactions: Erythema, pain, and edema at the injection site were reported in 1% of patients on Xofigo Secondary Malignant Neoplasms: Xofigo contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure may be associated with an increased risk of cancer and hereditary defects. Due to its mechanism of action and neoplastic changes, including osteosarcomas, in rats following administration of radium-223 dichloride, Xofigo may increase the risk of osteosarcoma or other secondary malignant neoplasms. However, the overall incidence of new malignancies in the randomized trial was lower on the Xofigo arm compared to placebo (<1% vs 2%; respectively), but the expected latency period for the development of secondary malignancies exceeds the duration of follow-up for patients on the trial Subsequent Treatment With Cytotoxic Chemotherapy: In the randomized clinical trial, 16% of patients in the Xofigo group and 18% of patients in the placebo group received cytotoxic chemotherapy after completion of study treatments. Adequate safety monitoring and laboratory testing was not performed to assess how patients treated with Xofigo will tolerate subsequent cytotoxic chemotherapy Adverse Reactions: The most common adverse reactions (≥10%) in the Xofigo arm vs the placebo arm, respectively, were nausea (36% vs 35%), diarrhea (25% vs 15%), vomiting (19% vs 14%), and peripheral edema (13% vs 10%). Grade 3 and 4 adverse events were reported in 57% of Xofigo-treated patients and 63% of placebo-treated patients. The most common hematologic laboratory abnormalities in the Xofigo arm (≥10%) vs the placebo arm, respectively, were anemia (93% vs 88%), lymphocytopenia (72% vs 53%), leukopenia (35% vs 10%), thrombocytopenia (31% vs 22%), and neutropenia (18% vs 5%) Please see the full Prescribing Information for Xofigo (radium Ra 223 dichloride). About Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. 1 In 2020, about 192,000 men in the U.S. were diagnosed with prostate cancer and an estimated 33,000 have died from the disease. 4 Prostate cancer is the fifth leading cause of death from cancer in men. 1 Prostate cancer results from the abnormal proliferation of cells within the prostate gland, which is part of a man’s reproductive system. 5 It mainly affects men over the age of 50, and the risk increases with age. 6 Treatment options range from surgery to radiation treatment to therapy using hormone-receptor antagonists, i.e., substances that stop the formation of testosterone or prevent its effect at the target location. 7 However, in nearly all cases, the cancer eventually becomes resistant to conventional hormone therapy. 8 Castration-resistant prostate cancer (CRPC) is an advanced form of the disease where the cancer keeps progressing even when the amount of testosterone is reduced to very low levels in the body. The field of treatment options for castration-resistant patients is evolving rapidly for CRPC patients who have prostate cancer that has not spread to other parts of the body with rising prostate-specific antigen (PSA) levels despite a castrate testosterone level, which is called non-metastatic castration-resistant prostate cancer, or nmCRPC. 9,10 About one-third of men with nmCRPC go on to develop metastases within two years. 11 In men with progressive nmCRPC, a short PSA doubling time is correlated with shortened time to first metastasis and death. 10 About Oncology at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.us. © 2021 Bayer BAYER, the Bayer Cross, NUBEQA and Xofigo are registered trademarks of Bayer. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. ——————————————————————————————————————————————————————————————————————————————————————————————— References GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018. Prostate Cancer. https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21492. Accessed January 2021.NUBEQA ® (darolutamide) tablets [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, January 2021.XOFIGO ® (radium-223 dichloride) Injection [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, December 2019.American Cancer Society. Cancer Facts & Figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed January 2021.American Cancer Society. What is Prostate Cancer? https://www.cancer.org/content/dam/CRC/PDF/Public/8793.00.pdf. Accessed January 2021.American Cancer Society. Prostate Cancer Risk Factors. https://www.cancer.org/content/dam/CRC/PDF/Public/8794.00.pdf. Accessed January 2021.National Cancer Institute. Hormone Therapy for Prostate Cancer. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet. Accessed January 2021.Nakazawa, Mary; Paller, Channing; Kyprianou, Natasha. Mechanisms of Therapeutic Resistance in Prostate Cancer. Curr Oncol Rep (2017) 19:13.Mayo Clinic. Prostate cancer screening: Should you get a PSA test?. https://www.mayoclinic.org/tests-procedures/psa-test/in-depth/prostate-cancer/art-20048087. Accessed January 2021.Howard, Lauren; Moreira, Daniel M; DeHoedt, Amanda; Aronson, William J., et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int 2017;120: E80-E86.Kirby, Mike, Hirst, Ceri, Crawford. E. David. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192. doi:10.1111/j.1742-1241.2011.02799. PP-PF-ONC-US-1672-1 2/21 View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005889/en/ CONTACT: Rose Talarico, Tel. +1 862.404.5302 E-Mail:[email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: HEALTH SCIENCE RESEARCH CLINICAL TRIALS ONCOLOGY SOURCE: Bayer Copyright Business Wire 2021. PUB: 02/08/2021 05:00 PM/DISC: 02/08/2021 05:00 PM http://www.businesswire.com/news/home/20210208005889/en WHIPPANY, N.J.–(BUSINESS WIRE)–Feb 8, 2021– Bayer announced today that new NUBEQA ® (darolutamide) and Xofigo ® (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place from February 11-13, 2021. Among featured presentations are additional Phase III ARAMIS trial analyses evaluating the crossover effect from placebo to NUBEQA and safety follow-up in men with non-metastatic castration-resistant prostate cancer (nmCRPC). Prostate cancer is the second most commonly diagnosed cancer in men and a key area of focus for Bayer. 1 The data that will be showcased at ASCO GU 2021 further build on the company’s ongoing research in areas of unmet need in this patient population. An oncology leader, Bayer’s prostate cancer portfolio is pivotal to the company’s wider commitment to exploring key areas of innovation, such as cell and gene therapy and targeted alpha therapies, with the ultimate goal to help people living with cancer. “Our priority at Bayer is to advance the treatment of men with prostate cancer across the disease continuum. The focus of our data at ASCO GU 2021 is reflective of our patient-centric approach to prostate cancer research,” said Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer’s Pharmaceutical Division. “We look forward to presenting our newest research, which is encouraging for the prostate cancer community.” Notable data that will be presented at the meeting is listed below. More details on meeting registration can be found here. Darolutamide Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS TrialAbstract 240; February 11, 8:00am EST and 4:30pm EST A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress– Investigator-Initiated Research (IIR)Abstract TPS182; February 11, 8:00am EST Clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223) early versus late in the treatment sequenceAbstract 136; February 11, 8:00am EST Twitter WhatsApp Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results– Investigator-Initiated Research (IIR)Abstract 135;February 11, 8:00am EST and 4:30pm EST Radium Ra 223 dichloride Synergistic antitumor effect of radium-223 and enzalutamide in the intratibial LNCaP prostate cancer xenograft modelAbstract 105; February 11, 8:00am EST TAGS  Local NewsBusiness Previous articleAZEK’s FULL-CIRCLE PVC Recycling Program Named a 2021 Green Innovation of the Year by Green Builder MediaNext articleExelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma Digital AIM Web Support Hematological Evaluation: Monitor blood counts at baseline and prior to every dose of Xofigo. Prior to first administering Xofigo, the absolute neutrophil count (ANC) should be ≥1.5 × 10 9 /L, the platelet count ≥100 × 10 9 /L, and hemoglobin ≥10 g/dL. Prior to subsequent administrations, the ANC should be ≥1 × 10 9 /L and the platelet count ≥50 × 10 9 /L. Discontinue Xofigo if hematologic values do not recover within 6 to 8 weeks after the last administration despite receiving supportive care Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer– Investigator-Initiated Research (IIR)Abstract 98; February 11, 8:00am EST Facebooklast_img read more

Metros With the Highest Credit Scores

first_img Demand Propels Home Prices Upward 1 day ago The Best Markets For Residential Property Investors 2 days ago Metros With the Highest Credit Scores Demand Propels Home Prices Upward 1 day ago Data Provider Black Knight to Acquire Top of Mind 1 day ago Governmental Measures Target Expanded Access to Affordable Housing 2 days ago 2021-03-03 Christina Hughes Babb About Author: Christina Hughes Babb Servicers Navigate the Post-Pandemic World 1 day ago Data Provider Black Knight to Acquire Top of Mind 1 day ago Credit health is key when it comes to achieving homeownership, and while it isn’t the only indicator, a credit score is an effective barometer used widely by creditors and lenders to weigh an applicant’s financial risk. Researchers at WalletHub studied more than 2500 American cities and ranked them according to credit score.Adam McCann, a financial writer for WalletHub adds the caveat that credit scores aren’t solely a reflection of responsibility.”It’s possible to have your credit score drop due to financial hardship that’s out of your control,” McCann wrote. “Luckily, research shows that the government stimulus in response to the COVID-19 pandemic actually helped increase the average credit score in 2020, in part due to enabling record-high debt paydowns.”It is important to add that other recent studies have added insight into how lenders assess credit. For example, the Urban Institute studied the importance of expanding access to mortgage credit to make homeownership more attainable for minority demographics—researchers there say that to truly capture the borrowers’ creditworthiness, “the housing industry must rethink how it qualifies borrowers for mortgages, update current credit scoring models, take into account additional data such as on-time rental payments, reexamine how it takes a borrower’s debt-to-income ratio into account, and more fully count the income of those who are self-employed or have gig-economy income.” Another study by the same organization explored the pandemic’s disproportionate impact on persons of color.That said, when looking solely at credit scores, cities in Florida and Arizona occupy the top four spots for high credit scores—that’s The Villages, Florida; Sun City West, Arizona; Sun City Center, Florida; and Green Valley, AZ—followed by Los Altos, California at No. 5, according to WalletHub.Hover over your area on the map to see where it stands on the list:Source: WalletHubWhile several experts interviewed by WalletHub agree that there is no quick fix for wanting credit scores, Ann Holmes (Assistant Dean, Finance and Administration at University of Maryland’s College of Behavioral and Social Sciences) says consumers who are able to improve their “utilization rate” could experience quick positive effects.”There are only two ways to do this,” Holmes said. “Pay down your outstanding balances to as low as possible and/or call your credit card company and ask them if they would consider increases the amount of your available credit. That will impact your credit score quickly.”Borrowers hoping to improve credit scores and overall creditworthiness must remain patient and vigilant when it comes to good financial habits, the panel of financial pundits who offered insight agreed.”I think the biggest mistake people make is that they think building the credit score or going from a bad credit score to a good one is going to happen overnight,” said Jamie Wagner (Assistant Professor Director, Center for Economic Education, Department of Economics at the University of Nebraska at Omaha). “It is going to take a long time and it takes diligence. It is not just changing a few things, it is committing to better financial behaviors including being mindful with budgeting and sticking to the budget, being careful with credit cards, and thinking about the long-term financial goals. Finances are a long-term game.” in Daily Dose, Featured, Market Studies, News Previous: Single Women’s Increasing Impact on the Housing Market Next: Best Homes Title, Schneiderman & Sherman Expand Corporate Team Subscribe The Week Ahead: Nearing the Forbearance Exit 2 days ago  Print This Post Governmental Measures Target Expanded Access to Affordable Housing 2 days ago Christina Hughes Babb is a reporter for DS News and MReport. A graduate of Southern Methodist University, she has been a reporter, editor, and publisher in the Dallas area for more than 15 years. During her 10 years at Advocate Media and Dallas Magazine, she published thousands of articles covering local politics, real estate, development, crime, the arts, entertainment, and human interest, among other topics. She has won two national Mayborn School of Journalism Ten Spurs awards for nonfiction, and has penned pieces for Texas Monthly, Salon.com, Dallas Observer, Edible, and the Dallas Morning News, among others. Servicers Navigate the Post-Pandemic World 1 day ago March 3, 2021 2,237 Views Share Save Sign up for DS News Daily Home / Daily Dose / Metros With the Highest Credit Scores The Best Markets For Residential Property Investors 2 days ago Related Articleslast_img read more

BCI Notifies Mediation With Conciliation As Compulsory Subject For LLB Courses Wef Academic Session 2020-21 [Read Letter]

first_imgNews UpdatesBCI Notifies Mediation With Conciliation As Compulsory Subject For LLB Courses Wef Academic Session 2020-21 [Read Letter] Akshita Saxena15 Aug 2020 9:33 PMShare This – xThe Bar Council of India has notified that “Mediation with Conciliation” shall be a compulsory subject to be taught with effect from the Academic Session 2020- 2021 in LL.B. degree course/s. It is intimated that the subject shall be a “45 hours course component”, mandatory for 3 year and 5 year course/s, both for Honours degree and the non-Honours one. The Council has emphasized on…Your free access to Live Law has expiredTo read the article, get a premium account.Your Subscription Supports Independent JournalismSubscription starts from ₹ 599+GST (For 6 Months)View PlansPremium account gives you:Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.Subscribe NowAlready a subscriber?LoginThe Bar Council of India has notified that “Mediation with Conciliation” shall be a compulsory subject to be taught with effect from the Academic Session 2020- 2021 in LL.B. degree course/s. It is intimated that the subject shall be a “45 hours course component”, mandatory for 3 year and 5 year course/s, both for Honours degree and the non-Honours one. The Council has emphasized on the need to train students in the “art” of Mediation and Conciliation to pave the way for reforms in the Indian Legal System, including reduction of burden on courts and quick and efficacious resolution being agreed upon by parties in disputes having varied points of conflict. It is cautioned therefore that the teachers for such programs must be rained adequately. “The qualification of teachers required to teach Mediation with Conciliation shall be decided by the Bar Council of India in consultation with any authority/institution as it may deem fit including U.G.C. For the moment, applications may be invited from the lawyers having at least 10 years of practice with theoretical knowledge and practical experience in these subjects, inclusive of trained Mediators/Conciliators, and from persons having 2- years LL.M Degrees in these subjects,” a letter addressed by the BCI to the Vice Chancellors of all such Universities issuing LL.B Degrees stipulates. Syllabus and the weekly course schedule for the subject, as recommended by the BCI may be accessed in the letter attached below. The move comes in the backdrop of suspended court functioning amid the pandemic, which brought Mediation as a tool for conflict resolution has come to the fore. “Mediation and Conciliation has been seen to lead to resolutions without undergoing arduous trials and moreover resolutions/solutions are arrived at, at a relatively lesser time. The Hon’ble Chief Justice of India is also keen that the art of Mediation is taught to LL.B students as it will go a long way in reducing the backlog and flood of cases. With litigants, students and Lawyers being more aware and keen about Mediation, this will be looked upon more as an option instead of filing suits/cases straight away,” the BCI said. ClickHere To Download Letter [Read Letter] Next Storylast_img read more